ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Drugmakers Offer Compounds For R&D

by Michael McCoy
July 28, 2014 | APPEARED IN VOLUME 92, ISSUE 30

[+]Enlarge
Credit: UCB
Compounds from UCB will be available to U.K. researchers.
09230-buscon-LaboPeoplecxd.jpg
Credit: UCB
Compounds from UCB will be available to U.K. researchers.

Seven drug companies are making “deprioritized” compounds available to British researchers through a new agreement with the U.K.’s Medical Research Council. AstraZeneca, GlaxoSmithKline, Janssen, Eli Lilly & Co., Pfizer, Takeda, and UCB will each provide MRC with a number of molecules they are no longer developing. Academic scientists then can apply for MRC funding to use them in research projects. The program builds on an earlier compound-sharing agreement between MRC and AstraZeneca.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment